Enjoy complimentary customisation on priority with our Enterprise License!
The diffuse large b-cell lymphoma (dlbcl) therapeutics market size is forecast to increase by USD2.25 billion at a CAGR of 8.09% between 2023 and 2028. The market is experiencing significant advancements due to several key factors. The growing geriatric population, with an increased susceptibility to lymphoma, is a significant driver for market growth. Technological advances have led to the development of innovative treatments, such as Zilotomab vedotin, which selectively targets lymphoid tissue in lymph nodes, bone marrow, and the thymus. The cytotoxicity of these drugs, which enables the destruction of cancer cells, is a major market trend. Furthermore, there is a growing preference for radiation treatments due to their ability to precisely target affected areas, minimizing damage to healthy cells. These factors collectively contribute to the growth and evolution of the DLBCL therapeutics market.
_therapeutics_market_size_abstract_2024_v1.jpg.webp?v4.1.20)
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.